文献速递临床试验与 GCP流行病学与生物统计

DESiGN试验(小于胎龄儿检测):评估生长评估方案(GAP)效果的随机对照试验研究方案

The DESiGN trial (DEtection of Small for Gestational age Neonate), evaluating the effect of the Growth Assessment Protocol (GAP): study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2019-03-04

DESiGN试验是首个评估GAP方案产前超声检测小于胎龄儿(SGA)临床效果、卫生经济学与实施情况的整群随机对照试验。研究以产科单位或国民健康服务体系信托为整群随机分组,比较GAP方案与标准护理。主要结局为按人群标准和定制标准均判定为SGA的婴儿的产前超声检出率。

要点

  • GAP方案包含SGA风险评估和使用定制宫高生长曲线图筛查。
  • 主要结局为按人群标准和定制标准均判定为SGA婴儿的产前超声检出率。
  • 观察性研究提示GAP使用率高的地区死产率降低22%。

核心结论

  • 本研究将首次提供随机对照试验数据,比较GAP方案与标准护理在产前超声检测SGA婴儿方面的潜在差异。
  • 关于GAP方案性能和服务提供要求的准确信息,有可能为国家减少死产率的政策决策提供依据。

研究设计与样本

  • 整群随机对照试验,以产科单位或国民健康服务体系信托为整群进行随机分组。
  • 整群随机分配至实施GAP方案组或标准护理组。
  • 研究将评估GAP方案产前检测SGA的临床效果、卫生经济学与实施情况。
  • 将进行定性访谈评估实施GAP的促进因素和障碍。
  • 试验注册号ISRCTN 67698474,注册日期2016年11月2日。

主要发现

  • 主要结局为按人群标准和定制标准均判定为SGA的婴儿的产前超声检出率。
  • 次要结局包括按人群百分位产前检出SGA、按定制百分位产前检出SGA、短期母婴结局、资源使用和经济后果,以及GAP实施的过程评价。
  • 观察性研究提示,在GAP使用率高的英国地区,使用GAP提高SGA检出与死产率降低22%相关。

关键数值与推荐

  • 主要结局为按人群标准和定制标准均判定为SGA的婴儿的产前超声检出率。
  • 次要结局包括按人群百分位和定制百分位分别产前检出SGA。
  • 次要结局包括短期母婴结局、资源使用和经济后果、GAP实施的过程评价。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stillbirth rates in the United Kingdom (UK) are amongst the highest of all developed nations. The association between small-for-gestational-age (SGA) foetuses and stillbirth is well established, and observational studies suggest that improved antenatal detection of SGA babies may halve the stillbirth rate. The Growth Assessment Protocol (GAP) describes a complex intervention that includes risk assessment for SGA and screening using customised fundal-height growth charts. Increased detection of SGA from the use of GAP has been implicated in the reduction of stillbirth rates by 22%, in observational studies of UK regions where GAP uptake was high. This study will be the first randomised controlled trial examining the clinical efficacy, health economics and implementation of the GAP programme in the antenatal detection of SGA. METHODS/DESIGN: In this randomised controlled trial, clusters comprising a maternity unit (or National Health Service Trust) were randomised to either implementation of the GAP programme, or standard care. The primary outcome is the rate of antenatal ultrasound detection of SGA in infants found to be SGA at birth by both population and customised standards, as this is recognised as being the group with highest risk for perinatal morbidity and mortality. Secondary outcomes include antenatal detection of SGA by population centiles, antenatal detection of SGA by customised centiles, short-term maternal and neonatal outcomes, resource use and economic consequences, and a process evaluation of GAP implementation. Qualitative interviews will be performed to assess facilitators and barriers to implementation of GAP. DISCUSSION: This study will be the first to provide data and outcomes from a randomised controlled trial investigating the potential difference between the GAP programme compared to standard care for antenatal ultrasound detection of SGA infants. Accurate information on the performance and service provision requirements of the GAP protocol has the potential to inform national policy decisions on methods to reduce the rate of stillbirth. TRIAL REGISTRATION: Primary registry and trial identifying number: ISRCTN 67698474 . Registered on 2 November 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Vieira MC, Relph S, Copas A, et al. The DESiGN trial (DEtection of Small for Gestational age Neonate), evaluating the effect of the Growth Assessment Protocol (GAP): study protocol for a randomised controlled trial. Trials. 2019. PMID: 30832739. doi:10.1186/s13063-019-3242-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。